U.S. health insurer shares dropped sharply after the Centers for Medicare & Medicaid Services (CMS) released a proposal projecting a net average year-over-year Medicare Advantage (MA) payment increase of 0.09% for calendar year 2027 — a figure that translates to just over $700 million in additional payments across the program.
The move jolted investors because Medicare Advantage is a central profit engine for many insurers, and markets had been positioned for a larger uplift. In early trading and subsequent coverage, names including UnitedHealth and Humana were among those hit hardest as analysts recalibrated expectations for 2027 revenue and margins.
CMS framed the proposal as a set of routine and technical updates aimed at maintaining payment accuracy and sustainability. The agency’s advance notice reflects multiple components that feed the final payment impact, including growth rates of underlying costs, quality bonus payments tied to Star Ratings, and updates to risk adjustment.
The market reaction also underscores how sensitive the sector has become to policy risk. Medicare Advantage has grown into a dominant coverage option for seniors, meaning even small percentage changes can ripple through corporate forecasts, benefit designs and investor sentiment.
Industry groups criticized the proposal, warning it could translate into tighter benefit offerings or higher costs for beneficiaries if plans attempt to protect profitability. Insurers have also faced ongoing political pressure over allegations that some Medicare Advantage practices inflate payments, a debate that has sparked investigations and congressional scrutiny.
CMS has not finalized the 2027 rate setting. The figure in the advance notice is a proposal and may be adjusted later in 2026 after feedback from stakeholders, public comments and additional analysis. Still, the immediate selloff shows investors treating the initial signal as meaningful, particularly amid a broader climate of healthcare cost containment.
For consumers, the ultimate question will be how much of the rate pressure ends up reflected in 2027 plan premiums, supplemental benefits, and provider networks. For insurers, the question is whether they can adapt through pricing, cost controls and product redesign without losing enrollment share in a program where competition is intense and regulatory scrutiny is rising.